Prostate disease risk factors among a New Zealand cohort

Journal of Nutrigenetics and Nutrigenomics

Volumn 5, Issue 6, 2013, Pages 339-351

  Karunasinghe, Nishi ^a   Han, Dug Yeo ^b   Goudie, Megan ^c   Zhu, Shuoton ^a   Bishop, Karen ^a   Wang, Alice ^a   Duan, He ^a   Lange, Katja ^b   Ko, Sarah ^b   Medhora, Roxanne ^b   Kan, Shiu Theng ^b   Masters, Jonathan ^c   Ferguson, Lynnette R ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Age; Glutathione peroxidase activity; Prostate disease; Selenium; Single nucleotide polymorphisms; Smoking; Thioredoxin reductase activity

Indexed keywords

ANTIOXIDANT; CATALASE; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; SELENIUM; THIOREDOXIN REDUCTASE; GLUTATHIONE PEROXIDASE 1;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BLOOD LEVEL; CANCER RISK; CAT GENE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; ENZYME ACTIVITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GPX1 GENE; GROUPS BY AGE; HEALTH STATUS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; METABOLISM; NEW ZEALAND; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; RISK ASSESSMENT; RISK FACTOR; SEL15 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CANCER GENETICS; ENZYME ACTIVATION; GENE FREQUENCY; GENOTYPE; GPX4 GENE; HEMOLYSATE; MALE; SELENIUM BLOOD LEVEL; SELS GENE; SEP15 GENE; SEPP1 GENE; SOD2 GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; CATALASE; COHORT STUDIES; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; SELENOPROTEINS; SMOKING;

EID: 84873037407     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000346279     Document Type: Article

References (57)

1. Ministry of Health: Cancer: New registrations and deaths 2008. Wellington, New Zealand: Ministry of Health 2011.
2. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN, Schaid DJ: Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000; 67: 82-91. (Pubitemid 30481546)
3. Cooney KA, McCarthy JD, Lange E, Huang L, Miesfeldt S, Montie JE, Oesterling JE, Sandler HM, Lange K: Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997; 89: 955-959. (Pubitemid 27282068)
4. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L, Ostrander EA: Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64: 776-787. (Pubitemid 30460420)
5. Hsieh CL, Oakley-Girvan I, Gallagher RP, Wu AH, Kolonel LN, Teh CZ, Halpern J, West DW, Paffenbarger RS Jr, Whittemore AS: Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997; 89: 1893-1894.
6. Schaid DJ: The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13:R103-R121. (Pubitemid 38443804)
7. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi OP, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Gronberg H, Emanuelsson M, Damber JE, Bergh A, Jonsson BA, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M, Trent J: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175-179. (Pubitemid 28455451)
8. Schmid HP, Fischer C, Engeler DS, Bendhack ML, Schmitz-Drager BJ: Nutritional aspects of primary prostate cancer prevention. Recent Results Cancer Res 2011; 188: 101-107.
9. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 1957-1963. (Pubitemid 26427723)
10. Hardin J, Cheng I, Witte JS: Impact of consumption of vegetable, fruit, grain, and high glycemic index foods on aggressive prostate cancer risk. Nutr Cancer 2011; 63: 860-872.
11. Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L: Dietary transfatty acids and cancer risk. Eur J Cancer Prev 2011; 20: 530-538.
12. Etminan M, FitzGerald JM, Gleave M, Chambers K: Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 2005; 16: 1125-1131. (Pubitemid 41356011)
13. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probst-field JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
14. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH: Loss of heterozygosity of the human cyto-solic glutathione peroxidase I gene in lung cancer. Carcinogenesis 1994; 15: 2769-2773.
15. Meplan C, Crosley LK, Nicol F, Horgan GW, Mathers JC, Arthur JR, Hesketh JE: Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex. Am J Clin Nutr 2008; 87: 1019-1027. (Pubitemid 351549249)
16. Meplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers JC, Hesketh JE: Relative abundance of seleno-protein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 2009; 11: 2631-2640.
17. Mostert V, Lombeck I, Abel J: A novel method for the purification of selenoprotein P from human plasma. Arch Biochem Biophys 1998; 357: 326-330. (Pubitemid 28419215)
18. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, Diamond AM, Gladyshev VN: Structure-expression relationships of the 15-kDa seleno-protein gene. Possible role of the protein in cancer etiology J Biol Chem 2000; 275: 35540-35547.
19. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM, Cai G, Mahaney MC, Comuzzie AG, Dyer TD, Walder KR, Zimmet P, MacCluer JW, Collier GR, Kissebah AH, Blangero J: Genetic variation in seleno-protein S influences inflammatory response. Nat Genet 2005; 37: 1234-1241. (Pubitemid 41568706)
20. Chen J, Cao Q, Qin C, Shao P, Wu Y, Wang M, Zhang Z, Yin C: GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis. J Cancer Res Clin Oncol 2011; 137: 1553-1561.
21. HapMap: Generic genome browser version. http://hapmap.ncbi.nlm.nih.gov/ cgi-perl/gbrowse/hapmap28-B36/.
22. Rongpu Y, Jiachen H, Gongkan F, Zhengen M: Fluorometric determination of micro-amounts of selenium in human blood, using 2, 3-diaminonaphthalene. Med Lab Sci 1986; 43: 331-334. (Pubitemid 16031758)
23. Watkinson JH: Semi-automated fluorimetric determination of nanogram quantities of selenium in biological materials. Anal Chim Acta 1979; 105: 319-325. (Pubitemid 9139554)
24. Watkinson JH, Brown MW: New phase separating device and other improvements in the semi-automated fluo-rimetric determination of selenium. Anal Chim Acta 1979; 105: 451-454.
25. Karunasinghe N, Ferguson LR, Tuckey J, Masters J: Hemolysate thioredoxin reductase and glutathione perox-idase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. J Nutr 2006; 136: 2232-2235. (Pubitemid 44156830)
26. Wendel A: Glutathione peroxidase. Methods Enzymol 1981; 77: 325-333.
27. Smith AD, Levander OA: High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol 2002;347: 113-121. (Pubitemid 34233267)
28. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2011.
29. Leitzmann MF, Rohrmann S: Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol 2012; 4: 1-11.
30. Braithwaite D, Boffetta P, Rebbeck TR, Meyskens F: Cancer prevention for global health: a report from the ASPO International Cancer Prevention Interest Group. Cancer Epidemiol Biomarkers Prev 2012; 21: 1606-1610.
31. International Agency for Research on Cancer (IARC): IARC Monographs on the Evaluation of Carcinogenic Risks in Human. Tobacco Smoke and Involuntary Smoking. Lyon, IARC Press, vol. 83, 2004.
32. Rota M, Scotti L, Turati F, Tramacere I, Islami F, Bellocco R, Negri E, Corrao G, Boffetta P, La Vecchia C, Bagnardi V: Alcohol consumption and prostate cancer risk: a meta-analysis of the dose-risk relation. Eur J Cancer Prev 2012; 21: 350-359.
33. Meyer HA, Hollenbach B, Stephan C, Endermann T, Morgenthaler NG, Cammann H, Kohrle J, Jung K, Schomburg L: Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2009; 18: 2386-2390.
34. Steinbrecher A, Méplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, Akesson B, Rohrmann S, Linseisen J: Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010; 19: 2958-2968.
35. Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM Jr: Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila) 2011; 4: 1761-1769.
36. Karunasinghe N, Ryan J, Tuckey J, Masters J, Jamieson M, Clarke LC, Marshall JR, Ferguson LR: DNA stability and serum selenium levels in a high-risk group for prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 391-397. (Pubitemid 38737464)
37. Karunasinghe N, Han DY, Zhu S, Yu J, Lange K, Duan H, Medhora R, Singh N, Kan J, Alzaher W, Chen B, Ko S, Triggs CM, Ferguson LR: Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr 2012; 7: 179-190.
38. Takata Y, Morris JS, King IB, Kristal AR, Lin DW, Peters U: Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue. Prostate 2009; 69: 1635-1642.
39. Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, Banev S, Petrovski D, Dzikova S, Georgiev V, Sikole A, Ozgok Y, Suturkova L, Dimovski AJ, Aydin A: Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem 2009; 42: 1228-1235.
40. Fernandez-Pachon MS, Berna G, Otaolaurruchi E, Troncoso AM, Martin F, Garcia-Parrilla MC: Changes in anti-oxidant endogenous enzymes (activity and gene expression levels) after repeated red wine intake. J Agric Food Chem 2009; 57: 6578-6583.
41. Peng FC, Tang SH, Huang MC, Chen CC, Kuo TL, Yin SJ: Oxidative status in patients with alcohol dependence: a clinical study in Taiwan. J Toxicol Environ Health A 2005; 68: 1497-1509.
42. Snook JT: Effect of ethanol use and other lifestyle variables on measures of selenium status. Alcohol 1991; 8: 13-16.
43. Apte MV, Zima T, Dooley S, Siegmund SV, Pandol SJ, Singer MV: Signal transduction in alcohol-related diseases. Alcohol Clin Exp Res 2005; 29: 1299-1309. (Pubitemid 41060449)
44. Ahn J, Nowell S, McCann SE, Yu J, Carter L, Lang NP, Kadlubar FF, Ratnasinghe LD, Ambrosone CB: Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006; 15: 1217-1222.
45. Bastaki M, Huen K, Manzanillo P, Chande N, Chen C, Balmes JR, Tager IB, Holland N: Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics 2006; 16: 279-286.
46. Nadif R, Mintz M, Jedlicka A, Bertrand JP, Kleeberger SR, Kauffmann F: Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic Res 2005; 39: 1345-1350. (Pubitemid 43023799)
47. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, Pummer K, Hubmer G: Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1, 127 patients. Urology 2003; 62: 451-455. (Pubitemid 36999867)
48. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
49. Go YM, Jones DP: Redox control systems in the nucleus: mechanisms and functions. Antioxid Redox Signal 2010; 13: 489-509.
50. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK: Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785. (Pubitemid 351416563)
51. Mukherjee A, Martin SG: The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 2008; 81:S57-S68.
52. Shan W, Zhong W, Zhao R, Oberley TD: Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression. Free Radic Biol Med 2010; 49: 2078-2087.
53. Hansen JM, Go YM, Jones DP: Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol 2006; 46: 215-234. (Pubitemid 43271189)
54. Hayashi T, Ueno Y, Okamoto T: Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 1993; 268: 11380-11388. (Pubitemid 23162336)
55. Schafer FQ, Buettner GR: Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001; 30: 1191-1212. (Pubitemid 32463931)
56. Cheung TH, Chung TK, Poon CS, Hampton GM, Wang VW, Wong YF: Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma. Cancer 1999; 86: 1294-1298. (Pubitemid 29447014)
57. Nagai H, Negrini M, Carter SL, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM: Detection and cloning of a common region of loss of heterozygosity at chromosome 1p in breast cancer. Cancer Res 1995; 55: 1752-1757.